Pfizer’s Women’s Health Initiative: Divest FemHRT And Contraceptive Line
Executive Summary
Pfizer plans to divest its hormone replacement therapy FemHRT during the first half of 2003
You may also be interested in...
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger
Galen buying Pfizer women’s health brands
Galen enters $359 mil. agreement with Pfizer to buy hormone replacement therapy FemHRT and oral contraceptives Estrostep and Loestrin. Galen could pay as much as an additional $125 mil. if products retain market exclusivity over course of patent life. Pfizer announced in January that it was seeking a buyer for the women's health line (1"The Pink Sheet" Jan. 27, p. 21). Galen's women's health line was recently expanded with purchase of Lilly's pre-menstrual dysphoric disorder therapy Sarafem (2"The Pink Sheet" Dec. 16, 2002, p. 34). Galen was an obvious bidder for the Pfizer brands: CEO Roger Boissonneault is a named inventor on three Estrostep and FemHRT product patents and on patent for credit card-style packaging for Loestrin and Estrostep, Galen says...